The administration of the CXCR4 antagonist AMD3100 correspondingly diminishes B lymphocyte accumulation and neutrophil infiltration in the lungs, thereby directly mitigating the progression of pulmonary fibrosis (91). The gene discussed is CXCR4; the disease is pulmonary fibrosis.